LIQUID PEDVAXHIB 125 MCG / 0.5 ML
NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN COMPLEX : 125 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP : 7.5 MCG / 0.5 ML · DIN 02235721 · MERCK CANADA INC
Health Canada status: CANCELLED POST MARKET
What is LIQUID PEDVAXHIB?
LIQUID PEDVAXHIB 125 MCG / 0.5 ML contains NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN COMPLEX : 125 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP : 7.5 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02235721, held by MERCK CANADA INC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 17-Feb-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LIQUID PEDVAXHIB used for?
Liquid PedvaxHIB® [Haemophilus b conjugate vaccine (meningococcal protein conjugate)] is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 59 months of age. As with other vaccines, several days following administration of Liquid PedvaxHIB® are required for protective levels of antibody to be achieved. Liquid PedvaxHIB® will not protect against Haemophilus influenzae other than type b or against other microorganisms that cause meningitis or sepsis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02235721 |
|---|---|
| Brand name | LIQUID PEDVAXHIB |
| Generic / active ingredient | NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN COMPLEX : 125 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP : 7.5 MCG / 0.5 ML |
| Manufacturer | MERCK CANADA INC |
| Strength | 125 MCG / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AG01 HEMOPHILUS INFLUENZAE B, PURIFIED ANTIG. CONJUGATED |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 17-Feb-2014 |
| Original market date | 1998-09-04 00:00:00 |
How is it stored and handled?
Store vaccine at 2°C - 8°C. DO NOT FREEZE.
How is it supplied?
box of five 0.5 mL single-dose vial of liquid vaccine
What can be used instead?
Other Canadian products sharing ATC code J07AG01 HEMOPHILUS INFLUENZAE B, PURIFIED ANTIG. CONJUGATED. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT-HIB | 30 MCG / 0.5 ML | KIT ; POWDER FOR SOLUTION | SANOFI PASTEUR LIMITED | MARKETED | DIN 01959034 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.